Zhibao Technology Inc. has signed a Memorandum of Understanding with DeSyn Protocol to co-develop compliant, secure Bitcoin-denominated yield products and institutional-grade BTC finance infrastructure. The partnership combines Zhibao's AI-driven risk management and InsurTech expertise with DeSyn's multi-chain asset management technology to create Bitcoin yield funds and risk protection frameworks. This collaboration aims to bridge traditional finance and Web3 by offering safer, transparent BTC yield strategies for institutional and retail investors. The agreement is subject to regulatory approvals and is expected to be formalized within 12 months.
Zhibao Technology Inc.'s strategic partnership news is presented here with Pluang's market data for context. For readers following US stocks, 68 rose and 81 fell out of 150 priced stocks on Pluang. Notable movers include Affirm Holdings Inc (AFRM) at USD 70.12 with a +2.98% change and a typical hold time of 21 days, Gold Fields Limited (GFI) at USD 39.61 with a -2.96% change and a buy order activity of 57%, and Rivian Automotive, Inc. (RIVN) at USD 15.45 with a +2.86% change and 100% buy order activity. Data is as of Sep 25, 2026 01:01 WIB.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
Western Union faces multiple analyst downgrades with price targets cut to as low as $6.00, reflecting concerns over its profitability and competitive pressures from fintech rivals. The stock has fallen over 15% in the past month, trading near $6.00, ...
Citigroup lowered ACADIA Pharmaceuticals' price target from $40 to $33 after its Alzheimer's drug remlifanserin missed the primary goal in a mid-stage trial, causing a 10.5% stock drop. Despite this, Citigroup kept a "Buy" rating, citing promising se...
